Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Abdominal pain: do not forget Thorotrast!

E Weber1, F Laarbaui, L Michel

  • 1Division of Internal Medicine and Endocrinology, University Hospital of Mont-Godinne, Yvoir, Belgium.

Postgraduate Medical Journal
|June 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Activated Raf-1 causes growth arrest in human small cell lung cancer cells.

The Journal of clinical investigation·1998
Same author

Assessment and management of urinary incontinence among homebound older adults: a clinical trial protocol.

Advanced practice nursing quarterly·1998
Same author

Cysteine proteinase inhibitor cystatin A in breast cancer.

Cancer research·1998
Same author

Investigations on immune parameters in welders.

Journal of applied toxicology : JAT·1998
Same author

Bulletin on women's health.

The American journal of nursing·1997
Same author

5-(N-oxyaza)-7-substituted-1,4-dihydroquinoxaline-2,3-diones: novel, systemically active and broad spectrum antagonists for NMDA/glycine, AMPA, and kainate receptors.

Journal of medicinal chemistry·1997

Thorotrast, a former contrast agent, is linked to various cancers, especially in the liver. This case highlights Thorotrast-induced hepatocarcinoma in an elderly woman, underscoring long-term risks.

Area of Science:

  • Radiology
  • Oncology
  • Toxicology

Background:

  • Thorotrast (25% thorium dioxide) was a widely used radiologic contrast agent until the mid-1950s.
  • Its use has been associated with a spectrum of malignancies, primarily of hepatic origin.
  • Understanding the long-term carcinogenic effects of Thorotrast is crucial for patient monitoring and risk assessment.

Observation:

  • An 82-year-old woman presented with a diagnosis of hepatocarcinoma.
  • Her medical history included exposure to Thorotrast during diagnostic procedures.
  • The clinical presentation was consistent with Thorotrast-induced liver cancer.

Findings:

  • The case confirms a direct link between past Thorotrast administration and the development of hepatocarcinoma.
  • Histopathological analysis supported the diagnosis of malignancy originating from liver cells.

Related Experiment Videos

  • This case adds to the body of evidence on Thorotrast's oncogenic potential.

    • Implications:

    • This case underscores the critical importance of considering Thorotrast exposure in patients with liver malignancies, even decades after administration.
    • It highlights the need for long-term surveillance in individuals with known Thorotrast exposure.
    • Further research into the mechanisms of Thorotrast-induced carcinogenesis may inform future strategies for managing radiation-related cancers.